Perspective: targeting VEGF-A and YKL-40 in glioblastoma – matter matters

References

• Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–466.
   PubMed Web of Science ®Google Scholar
• Shao R, Taylor SL, Oh DS, et al. Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization. Oncotarget. 2015;6:40507–40518.
   PubMedGoogle Scholar
• Wick W, Platten M, Wick A, et al. Current status and future directions of anti-angiogenic therapy for gliomas. Neuro Oncol. 2016;18(3):315–328.
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell. 2017;31(3):326–341.
   PubMed Web of Science ®Google Scholar
• Fecci PE, Sampson JH. The current state of immunotherapy for gliomas: an eye toward the future. J Neurosurg. 2019;131(3):657–666.
   PubMed Web of Science ®Google Scholar
• Wang N, Jain RK, Batchelor TT. New directions in anti-angiogenic therapy for glioblastoma. Neurotherapeutics. 2017;14(2):321–332.
   PubMed Web of Science ®Google Scholar
• Tamura R, Tanaka T, Miyake K, et al. Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response. Brain Tumor Pathol. 2017;34(2):62–77.
   PubMed Web of Science ®Google Scholar
• Thompson EM, Frenkel EP, Neuwelt EA. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology. 2011;76(1):87–93.
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708. .
   PubMed Web of Science ®Google Scholar
• Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370:709–722.
   PubMed Web of Science ®Google Scholar
• Piao Y, Liang J, Holmes L, et al. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res off J Am Assoc Cancer Res. 2013;19:4392–4403.
   PubMed Web of Science ®Google Scholar
• Michaelsen SR, Staberg M, Pedersen H, et al. VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance. Neuro Oncol. 2018;20:1462–1474.
   PubMed Web of Science ®Google Scholar
• Chandra A, Jahangiri A, Chen W, et al. Clonal ZEB1-driven mesenchymal transition promotes targetable oncologic anti-angiogenic therapy resistance. Cancer Res. 2020;80(7):1498–1511.
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110.
   PubMed Web of Science ®Google Scholar
• Wang Q, Hu B, Hu X, et al. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell. 2017;32(42–56.e6). DOI:10.1016/j.ccell.2017.06.003.
   Google Scholar
• Neftel C, Laffy J, Filbin MG, et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell. 2019;178:835–49.e21.
   PubMed Web of Science ®Google Scholar
• Lu KV, Chang JP, Parachoniak CA, et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell. 2012;22:21–35.
   PubMed Web of Science ®Google Scholar
• Faibish M, Francescone R, Bentley B, et al. A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther. 2011;10:742–751.
   PubMed Web of Science ®Google Scholar
• Wurm J, Behringer SP, Ravi VM, et al. Astrogliosis releases pro-oncogenic Chitinase 3-Like 1 causing MAPK signaling in glioblastoma. Cancers (Basel) 2019 11 10.3390/cancers11101437
   Web of Science ®Google Scholar
• Saidi A, Javerzat S, Bellahcene A, et al. Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int J Cancer. 2008;122:2187–2198.
   PubMed Web of Science ®Google Scholar
• Shao R, Francescone R, Ngernyuang N, et al. Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma. Carcinogenesis. 2014;35:373–382.
   PubMed Web of Science ®Google Scholar
• Francescone RA, Scully S, Faibish M, et al. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem. 2011;286:15332–15343.
   PubMed Web of Science ®Google Scholar
• Qin G, Li X, Chen Z, et al. Prognostic value of YKL-40 in patients with glioblastoma: a systematic review and meta-analysis. Mol Neurobiol. 2017;54(5):3264–3270.
   PubMed Web of Science ®Google Scholar
• Boisen MK, Holst CB, Consalvo N, et al. Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial. Oncotarget. 2018;9(6):6752–6762.
   PubMedGoogle Scholar
• Salamon J, Hoffmann T, Elies E, et al. Antibody directed against human YKL-40 increases tumor volume in a human melanoma xenograft model in scid mice. PloS One. 2014;9(4):e95822.
   PubMed Web of Science ®Google Scholar
• Bojesen SE, Johansen JS, Nordestgaard BG. Plasma YKL-40 levels in healthy subjects from the general population. Clin Chim Acta. 2011;412(9–10):709–712.
   PubMed Web of Science ®Google Scholar
• Kjaergaard AD, Nordestgaard BG, Johansen JS, et al. Observational and genetic plasma YKL-40 and cancer in 96,099 individuals from the general population. Int J Cancer. 2015;137(11):2696–2704.
   PubMed Web of Science ®Google Scholar
• Rasmussen RD, Gajjar MK, Tuckova L, et al. BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity. Nat Commun. 2016;7(1):13398.
   PubMedGoogle Scholar
• Holst CB, Brochner CB, Vitting-Seerup K, et al. Astrogliogenesis in human fetal brain: complex spatiotemporal immunoreactivity patterns of GFAP, S100, AQP 4 and YKL-40. J Anat. 2019;235(3):590–615.
   PubMed Web of Science ®Google Scholar
• Liao Y, Smyth GK, Shi W. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. Nucleic Acids Res. 2019;47(8):e47.
   PubMed Web of Science ®Google Scholar
• Patro R, Duggal G, Love MI, et al. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14(4):417–419.
   PubMed Web of Science ®Google Scholar
• Vitting-Seerup K, Sandelin A. The Landscape of Isoform Switches in Human Cancers. Mol Cancer Res. 2017;15(9):1206–1220.
   PubMed Web of Science ®Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
   PubMed Web of Science ®Google Scholar
• Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–140.
   PubMed Web of Science ®Google Scholar
• Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 2010;11(3):R25.
   PubMed Web of Science ®Google Scholar
• Lun AT, Chen Y, Smyth GK. It’s DE-licious: a recipe for differential expression analyses of RNA-seq experiments using quasi-likelihood methods in edgeR. Methods Mol Biol. 2016;1418:391–416.
   PubMedGoogle Scholar
• Liberzon A, Subramanian A, Pinchback R, et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739–1740.
   PubMed Web of Science ®Google Scholar
• Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet. 2000;25(1):25–29.
   PubMed Web of Science ®Google Scholar
• The Gene Ontology Consortium. Expansion of the gene ontology knowledgebase and resources. Nucleic Acids Res. 2017;45. D331-D8
   Web of Science ®Google Scholar
• Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.
   PubMed Web of Science ®Google Scholar
• Wu D, Smyth GK. Camera: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res. 2012;40(17):e133.
   PubMed Web of Science ®Google Scholar
• Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108–112.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47–e.
   PubMed Web of Science ®Google Scholar
• Smyth GK, Michaud J, Scott HS. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005;21(9):2067–2075.
   PubMed Web of Science ®Google Scholar
• Robertson FL, Marques-Torrejon MA, Morrison GM, et al. Experimental models and tools to tackle glioblastoma. Dis Model Mech. 2019;12(9):dmm040386.
   PubMed Web of Science ®Google Scholar
• Da Hora CC, Schweiger MW, Wurdinger T, et al. Patient-derived glioma models: from patients to dish to animals. Cells. 2019;8(10):1177.
   PubMed Web of Science ®Google Scholar
• Huszthy PC, Daphu I, Niclou SP, et al. In vivo models of primary brain tumors: pitfalls and perspectives. Neuro Oncol. 2012;14(8):979–993.
   PubMed Web of Science ®Google Scholar
• Stockhausen MT, Broholm H, Villingshoj M, et al. Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme. Exp Cell Res. 2011;317(11):1513–1526.
   PubMed Web of Science ®Google Scholar
• Henrik Heiland D, Ravi VM, Behringer SP, et al. Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma. Nat Commun. 2019;10(1):2541.
   PubMedGoogle Scholar
• Miyai M, Tomita H, Soeda A, et al. Current trends in mouse models of glioblastoma. J Neurooncol. 2017;135(3):423–432.
   PubMed Web of Science ®Google Scholar
• Mj S, Woolard K, Dh N, et al. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 2009;4(5):440–452.
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756–760.
   PubMed Web of Science ®Google Scholar
• Greenberg JI, Shields DJ, Barillas SG, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 2008;456(7223):809–813.
   PubMed Web of Science ®Google Scholar
• Junker N, Johansen JS, Hansen LT, et al. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci. 2005;96(3):183–190.
   PubMed Web of Science ®Google Scholar
• Chen CC, Llado V, Eurich K, et al. Carbohydrate-binding motif in chitinase 3-like 1 (CHI3L1/YKL-40) specifically activates Akt signaling pathway in colonic epithelial cells. Clin Immunol. 2011;140(3):268–275.
   PubMed Web of Science ®Google Scholar
• Urup T, Staunstrup LM, Michaelsen SR, et al. Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients. BMC Cancer. 2017;17(1):278.
   PubMedGoogle Scholar
• Bouwens Van Der Vlis TAM, Kros JM, Mustafa DAM, et al. The complement system in glioblastoma multiforme. Acta Neuropathol Commun. 2018;6(1):91.
   PubMedGoogle Scholar
• Kim DH, Park HJ, Lim S, et al. Regulation of chitinase-3-like-1 in T cell elicits Th1 and cytotoxic responses to inhibit lung metastasis. Nat Commun. 2018;9(1):503.
   PubMedGoogle Scholar
• Cohen N, Shani O, Raz Y, et al. Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1. Oncogene. 2017;36(31):4457–4468.
   PubMed Web of Science ®Google Scholar
• Elias JA. Chi3l1 regulation of checkpoint regulating, costimulatory and coinhibitory molecules in primary and metastatic lung cancer. Annual Report - US Army Medical Research and Material Command 2018.
   Google Scholar
• Ma B, Akosman B, Kamle S, et al. Chitinase 3-like-1 stimulates PD-L1 and other immune checkpoint inhibitors. bioRxiv. 2021. DOI:10.1101/2021.01.15.426788
   Google Scholar